A photo of Erin H. Breese.

Member, Division of Oncology

Assistant Professor, UC Department of Pediatrics

513-517-2234

513-636-3549

Board Certified

My Biography & Research

Biography

My work at Cincinnati Children’s stems from a desire to improve the quality of life and outcomes for children fighting cancer. I am board certified in both pediatrics and pediatric hematology/oncology.

Understanding the molecular drivers of leukemia, the adaptations that leukemia cells develop to become resistant to chemotherapy and its interactions with a patient’s immune system are key factors to improving cancer therapies. Appropriate therapy for pediatric leukemia requires a precision medicine approach to tailor therapy for the individual patient. Our leukemia/lymphoma team is constantly working locally, nationally and internationally to improve our options for therapy and decrease associated toxicities.

My research areas of interest are infant leukemia, the molecular biology of leukemia, KMT2A-rearranged leukemia, precision medicine and clinical trial development for high-risk and relapsed leukemia.

Additional Languages

French

Clinical Interests

Pediatric leukemia and lymphoma

Research Interests

Molecular pathogenesis of leukemia; novel therapeutics for childhood leukemia, especially for infants with MLL-rearranged leukemia

Academic Affiliation

Assistant Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Leukemia

Research Divisions

Oncology, Cancer and Blood Diseases

My Locations

My Education

PhD: Biochemistry & Molecular Biology, Indiana University, Indianapolis, IN, 2006.

MD: Indiana University, Indianapolis, IN, 2008.

Residency: Pediatrics, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, 2011.

Fellowship: Pediatric Hematology/Oncology, Stanford University School of Medicine, Lucile Packard Children’s Hospital, Palo Alto, CA, 2014.

Certification: American Board of Pediatrics, 2011; ABP Pediatric Hematology/Oncology, 2015.

My Publications

Experiences of a multidisciplinary genomic tumor board interpreting risk for underlying germline variants in tumor-only sequencing results. Fishler, KP; Breese, EH; Walters-Sen, L; McGowan, ML. JCO Precision Oncology. 2019; 3:1-8.

Capped antithrombin III dosing is cost effective in the management of asparaginase-associated thrombosis. Young, J; Sawyer, J; Jenkins, M; O'Brien, M; Luchtman-Jones, L; Breese, EH. Pediatric Blood and Cancer. 2019; 66:e27719-e27719.

Limitations of HLH-2004 criteria in distinguishing malignancy-associated hemophagocytic lymphohistiocytosis. Gurunathan, A; Boucher, AA; Mark, M; Prus, KM; O'Brien, MM; Breese, EH; Mizukawa, BE; Absalon, MJ; Nelson, AS; Jordan, MB; et al. Pediatric Blood and Cancer. 2018; 65:e27400-e27400.

MLL leukemia induction by t(9;11) chromosomal translocation in human hematopoietic stem cells using genome editing. Schneidawind, C; Jeong, J; Schneidawind, D; Kim, I; Duque-Afonso, J; Wong, SH K; Iwasaki, M; Breese, EH; Zehnder, JL; Porteus, M; et al. Blood Advances. 2018; 2:832-845.

Viral surveillance using PCR during treatment of AML and ALL. Dixon, SB; Lane, A; O'Brien, MM; Burns, KC; Mangino, JL; Breese, EH; Absalon, MJ; Perentesis, JP; Phillips, CL. Pediatric Blood and Cancer. 2018; 65:e26752-e26752.